206 related articles for article (PubMed ID: 16394581)
1. [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Tomoo T; Suzuki M
Nihon Yakurigaku Zasshi; 2005 Nov; 126(5):353-7. PubMed ID: 16394581
[No Abstract] [Full Text] [Related]
2. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
[No Abstract] [Full Text] [Related]
3. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak C
Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
[No Abstract] [Full Text] [Related]
5. Mismanagement of malignant hypercalcaemia.
Lightowlers S; Patterson D
Clin Med (Lond); 2013 Feb; 13(1):118. PubMed ID: 23472518
[No Abstract] [Full Text] [Related]
6. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Sakurai T
Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
8. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Wellington K; Goa KL
Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid: a review of its use in patients with advanced cancer.
Perry CM; Figgitt DP
Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Lin PH; Chiu CF; Lu YS
Ann Oncol; 2011 May; 22(5):1244-1246. PubMed ID: 21460375
[No Abstract] [Full Text] [Related]
12. Hypercalcemia and gallium nitrate.
Gucalp R
J Support Oncol; 2004; 2(6):518-20. PubMed ID: 16329218
[No Abstract] [Full Text] [Related]
13. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Neville-Webbe Hl; Coleman RE
Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
[TBL] [Abstract][Full Text] [Related]
14. [Zoledronic acid free adjustment according to renal function: results of pharmacists interventions].
Mora Atorrasagasti O; Lertxundi Etxeberria U; Peral Aguirregoitia J; MartÃnez Bengoechea MJ
Farm Hosp; 2007; 31(5):316-8. PubMed ID: 18052636
[No Abstract] [Full Text] [Related]
15. Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.
Nagy Z
Pathol Oncol Res; 2005; 11(3):186-7. PubMed ID: 16299941
[No Abstract] [Full Text] [Related]
16. Zoledronic acid.
Cheer SM; Noble S
Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
[TBL] [Abstract][Full Text] [Related]
17. Anticancer properties of zoledronic acid.
Green J; Lipton A
Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].
Shen G; Song ST; Jiang ZF; Bian SG; Xie GR; Wang YJ; Wang JJ
Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):632-4. PubMed ID: 16438878
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
Griz L; Colares V; Bandeira F
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
